Skip to main content
. 2021 Jan 16;20:228–239. doi: 10.1016/j.omto.2021.01.001

Figure 6.

Figure 6

YTHDF1-mediated cisplatin resistance is through promoting glutamine metabolism

(A) DLD-1 cells were transfected with control or YTHDF1 overexpression plasmid for 48 h. Cells were treated without or with BPTES for 24 h. The GLS activity was measured. (B) The above cells were treated with cisplatin at 0, 2.5, 5, 10, 20, or 40 μM for 48 h. Cell viability and death were assessed by an MTT assay and (C) annexin V assay, respectively. (D) LoVo cells were transfected with control or YTHDF1 overexpression plasmid for 48 h. Cells were treated without or with BPTES for 24 h. The GLS activity was measured. (E) The above cells were treated with cisplatin at 0, 2, 4, 8, 16, or 32 μM for 48 h. Cell viability and death were assessed by an MTT assay and (F) annexin V assay, respectively. Data are presented as mean ± SD. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001.